Evidence map›Paper›PMID 40047290›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025

Improved Orthogonality in Naphthalimide/Cyanine Dyad Boosts Superoxide Generation: a Tumor-Targeted Type-I Photosensitizer for Photodynamic Therapy of Tumor by Inducing Ferroptosis.

Guangxiao Yao, Junfeng Miao, Yingying Huo, Wei Guo

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Modern Cyanine Dye-Based Photosensitizers for Medical Applications.Angewandte Chemie (International ed. in English) · 2026
    Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Guangxiao YaoSchool of Chemistry and Chemical Engineering, Shanxi University, Taiyuan, 030006, China.
Junfeng MiaoSchool of Chemistry and Chemical Engineering, Shanxi University, Taiyuan, 030006, China.
Yingying HuoSchool of Chemistry and Chemical Engineering, Shanxi University, Taiyuan, 030006, China.
Wei GuoSchool of Chemistry and Chemical Engineering, Shanxi University, Taiyuan, 030006, China.ORCID https://orcid.org/0000-0002-3163-9742

Funding

Central and Local Scientific and Technological Development Foundation Z135050009017Key Laboratory of Photochemical Functional Molecules in Shanxi ProvinceNational Natural Science Foundation of China 21904082National Natural Science Foundation of China 22277070Science and Technology Innovation Talent Team Foundation of Shanxi Province 202304051001002
6 · The paper itself

Abstract

It is highly desired to achieve Type-I photosensitizer (PS) to overcome the hypoxic limitation found in most clinically used PSs. Herein, a new heavy-atom-free Type-I PS T-BNCy5 is presented by incorporating a biotin-modified naphthalimide (NI) unit into the meso-position of a N-benzyl-functionalized, strongly photon-capturing pentamethine cyanine (Cy5) dye. Such molecular engineering induces a rigid orthogonal geometry between NI and Cy5 units by introducing an intramolecular sandwich-like π-π stacking assembly, which effectively promotes intersystem crossing (ISC) and greatly extends the triplet-state lifetime (τ = 389 µs), thereby markedly improving the superoxide (O

Indexed as

CarbocyaninesFerroptosisNaphthalimidesNeoplasmsPhotochemotherapyPhotosensitizing AgentsSuperoxidesAnimalsCell Line, TumorHumansMiceCarbocyaninesNaphthalimidesPhotosensitizing AgentsSuperoxidesheptamethine cyaninenaphthalimidephotodynamic therapysuperoxidetumors

Identifiers

PMID40047290
PMCPMC12061322

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.